Search
Inhibrx Biosciences Inc
INBXAdd to Watchlist
93.050USD
-1.150-1.22%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.36BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Inhibrx Biosciences Inc is 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
277.500
Target Price
+198.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Inhibrx Biosciences Inc
INBX
3
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Inhibrx Biosciences Inc's price target?
Analysts forecast that Inhibrx Biosciences Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 12.00.
How have Inhibrx Biosciences IncINBX's recent earnings per share performed?
The market expectation was USD -2.15, while Inhibrx Biosciences IncINBX's earnings per share (EPS) for the previous quarter was USD -2.11. EPS for the next quarter is expected at USD -2.39.
What is the analyst rating for Inhibrx Biosciences Inc?
Based on the ratings of Inhibrx Biosciences Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
